Serum metabonomics study of chronic renal failure by ultra performance liquid chromatography coupled with Q-TOF mass spectrometry

Abstract

A metabonomics technique based on ultraperformance liquid chromatography (UPLC) coupled with Q-TOF mass spectrometry was employed to investigate the sera from 32 patients with chronic renal failure (CRF) without renal replacement therapy and 30 healthy volunteers in order to find potential disease biomarkers and reveal its pathophysiological changes. After data acquisition Waters MarkerLynx software was used to report retention time and m/z pairs for each metabolite peak, these data were exported to an excel table, then handled by using multivariate analysis and the statistical analysis in the SIMCA-P and the SPSS softwares to obtain potential biomarkers which were further identified by MS/MS. Seven potential biomarkers, creatinine, tryptophan, phenylalanine, kynurenine and three lysophosphatidylcholines, were identified. The results suggest that CRF can lead to the increase of reservation of creatinine in the body, and the abnormal metabolism of the two essential amino acids and lysophosphatidylcholines. It has indicated that metabonomics will be a powerful tool in the clinic research.

Fasting Serum Lipid and Dehydroepiandrosterone Sulfate as Important Metabolites for Detecting Isolated Postchallenge Diabetes: Serum Metabolomics via Ultra-High-Performance LC-MS

“…Therefore, low concentrations of lysoPC (18:2) may predict the risk of IPD. However, imbalance of lysoPC appears to be involved in several other metabolic disorders, and 3 lysoPC metabolites have been identified as markers of disorders such as chronic renal failure and Alzheimer disease (28,29 ). Hence, despite our finding that 3 lysoPC metabolites are critical for identifying IPD patients, the specificity of these metabolites may limit application in the clinical diagnosis of IPD.…”

UPLC-based metabonomic applications for discovering biomarkers of diseases in clinical chemistry

“…Increased LPC(18:0), phenylalanine and kynurenine and decreased LPC(16:0), LPC(18:1) and tryptophan were observed in chronic renal failure patients [76]. UPLC-based metabonomics was developed to analyze the plasma samples from end-stage renal disease patients.…”

Plasma Lipidomic Analysis to Identify Novel Biomarkers for Hepatocellular Carcinoma

“…In addition, down-regulation of LPC (18:2) in HCC patients has been observed in many other reports [11,12,35]. The disturbance of PC and LPC might attribute to the alteration of lysolecithin acyltransferase activity, the inhibition of phospholipase 2, the overexpression of lysophospholipase D/autotoxin, and the excess consumption of LPC in the inflammatory response [36][37][38]. Last but not least, four sphingolipids, including SM (39:1), LacCer (40:3), GalCer (36:5), and GalCer (36:3), were also altered in HCC patient group.…”